[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572805":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":40,"locations":31,"responsibleParty":47,"collaborators":31,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":31,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":31,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":79,"whyStopped":31,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":31},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexmedetomidine Group","EXPERIMENTAL","Participants in this group will receive a bolus dose of dexmedetomidine (0.5 µg\u002Fkg ideal body weight) diluted in 0.9% normal saline over 10 minutes before induction of anesthesia. This will be followed by a continuous infusion of dexmedetomidine at 0.5 µg\u002Fkg\u002Fh until 10 minutes before the end of surgery.",[13],"Drug: Dexmedetomidine infusion",{"label":15,"type":10,"description":16,"interventionNames":17},"Ketamine Group","Participants in this group will receive a bolus dose of ketamine (0.3 mg\u002Fkg ideal body weight) diluted in 0.9% normal saline over 10 minutes before induction of anesthesia. This will be followed by a continuous infusion of ketamine at 0.3 mg\u002Fkg\u002Fh until 10 minutes before the end of surgery.",[18],"Drug: Ketamine infusion",{"label":20,"type":21,"description":22,"interventionNames":23},"Control Group","PLACEBO_COMPARATOR","Participants in this group will receive a bolus dose of 0.9% normal saline over 10 minutes before induction of anesthesia. This will be followed by a continuous infusion of 0.9% normal saline until 10 minutes before the end of surgery.",[24],"Drug: Normal Saline Infusion (Placebo)",[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Dexmedetomidine infusion","A bolus dose of dexmedetomidine (0.5 µg\u002Fkg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.5 µg\u002Fkg\u002Fh until 10 minutes before the end of surgery.",[9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Ketamine infusion","A bolus dose of ketamine (0.3 mg\u002Fkg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.3 mg\u002Fkg\u002Fh until 10 minutes before the end of surgery.",[15],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Normal Saline Infusion (Placebo)","A bolus dose of 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion of 0.9% normal saline until 10 minutes before the end of surgery.",[20],[41],{"name":42,"role":43,"phone":44,"phoneExt":45,"email":46},"Ahmed A Shalaby, M.B.B.Ch","CONTACT","01020479848","+2","phdoc97@gmail.com",{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":51,"oldNameTitle":31,"oldOrganization":31},"PRINCIPAL_INVESTIGATOR","Ahmed Abdalla Shalaby","Anesthesiology, Intensive Care and Pain Management Resident","Menoufia University","100572805","dexmedetomidine-versus-ketamine-as-adjuvants-in-bariatric-surgery-100572805",false,"NCT06738043","Dexmedetomidine Versus Ketamine as Adjuvants in Bariatric Surgery","Dexmedetomidine Infusion Versus Low Dose Ketamine Infusion as an Adjuvant in Bariatric Surgery: A Randomized Controlled Comparative Study","Inclusion Criteria:\n\n* Patients aged 18-60 years.\n* Both sexes.\n* Body mass index (BMI) \\> 35 kg\u002Fm², scheduled for bariatric surgery.\n* American Society of Anesthesiologists (ASA) physical status I-II.\n\nExclusion Criteria:\n\n* History of hypersensitivity to dexmedetomidine or ketamine.\n* History of substance abuse or chronic opioid use.\n* American Society of Anesthesiologists (ASA) physical status III or IV.\n* Severe hepatic or renal impairment.\n* Cardiopulmonary disorders.\n* Severe diabetes mellitus.\n* Psychiatric disorders, seizures, uncontrolled hypertension (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg), or heart block.","ALL","18 Years","60 Years",{"count":63,"type":64},90,"ESTIMATED","INTERVENTIONAL",[67],"NA","This randomized controlled trial aims to compare the analgesic efficacy of dexmedetomidine infusion versus low-dose ketamine infusion as adjuvants in bariatric surgery. The study includes 90 patients undergoing bariatric surgery at Menoufia University Hospital, randomized into three groups: dexmedetomidine, ketamine, and control (placebo). Primary outcomes include total morphine consumption intra- and post-operatively. Secondary outcomes include postoperative pain scores, total analgesic consumption, time to first analgesic request, hemodynamic parameters, and patient satisfaction. This study seeks to explore safer, more effective pain management strategies to minimize opioid use in bariatric surgery patients.",[70,71,72],"Obesity","Postoperative Pain","Bariatric Surgery",[74,75,76,77,78],"Dexmedetomidine","Ketamine","Opioid-Sparing Analgesia","Randomized Controlled Trial","Pain Management","NOT_YET_RECRUITING","2026-04-05",{"date":82,"type":83},"2026-04-09","ACTUAL",{"date":85,"type":64},"2026-04-20",{"date":87,"type":64},"2027-04-20",{"name":5,"class":6}]